Machine learning-based systems biology identifies therapeutic kinase targets in clear cell renal cell carcinoma
Background: Heterogeneous Single-Cell Transcriptomic Landscape and Bottlenecks in Resistance Feedback Flux Data in Clear Cell Renal Cell Carcinoma (ccRCC) R&D
The mainstream paradigm in current ccRCC therapeutic R&D has been excessively biased towards inhibiting angiogenesis and blocking immune checkpoint pathways mediated by the tumor microenvironment (TME), failing to systematically identify and target the intrinsic genetic vulnerabilities of cancer cells. In particular, the conventional static single-omics analysis standard guidelines have critical limitations, including the noise induced by cellular dissociation during tissue dissociation, the distortion of single-lineage signal transduction estimation due to intratumoral heterogeneity, and the inability to proactively control the dynamic resistance feedback flux induced by long-term treatment with tyrosine kinase inhibitors in a in silico environment. This has led to consecutive failures in establishing treatment response baselines and predicting clinically effective concentrations, resulting in significant data barriers and bottlenecks, such as resource leakage in large-scale drug development pipelines and a surge in Phase 3 clinical trial failure rates.
Discovery: Implementation of a Multi-Dimensional Drug Proximity Pipeline and Demonstration of Single-Cell Resolution Multi-Omics Tensor Synchronization
This computational omics architecture constructs a drug proximity analysis machine learning pipeline that links single-cell RNA sequencing, protein-protein interaction networks, and drug-target distance into a multi-dimensional tensor. Molecular binding free energies are precisely tuned, and dynamic differential equations are used to proactively calculate rate constants in silico, thereby eliminating batch effects. After validation using whole-genome CRISPR knockout data and independent transcriptomic datasets (TCGA-KIRC), it was determined that ABL1, CDK4/6, and JAK inhibition induce apoptosis in ccRCC cell lines. Furthermore, it was demonstrated that the multi-combination of FDA-approved drugs, Ribociclib, Ponatinib, and Dasatinib, collapses the downstream transcriptomic network variation curve, which is a key rate-limiting node in cell cycle progression, thereby permanently inhibiting tumor growth and demonstrating molecular integrity.
Establishment of a Refined Layered Model for Coordinating ABL1 and CDK4/6 Signaling Pathways and Reversible Renal Filtration Homeostasis
Based on the omics matrix of individual patient cancer cells, a refined layered model was established to stratify molecular phenotypes according to VHL mutation status and PBRM1 and BAP1 status. By up- or down-regulating the effective reaction rate constants of the ABL1 and CDK4/6 signaling pathways, which are the tumor's survival pathways, a dynamic equilibrium protocol was implemented that can completely inactivate the metabolic bypass feedback stimulation that occurs when cancer cells are rapidly killed by combination drug treatment. This modeling enables the operation of a computational backbone that can prevent epithelial-mesenchymal transition in the renal filtration barrier and reversibly regulate and preserve renal hemodynamic homeostasis in a virtual patient in silico, even in metabolically stressed cancer cells.
Prospects: Establishing a Standard for Programmable Computational System Pharmacology and Launching a Next-Generation IND Digital Governance Framework
This governance framework is a groundbreaking starting point for establishing a next-generation standard for computational system pharmacology designed to overcome resistance in ccRCC patients, and it is a master framework for transforming static, reactive R&D governance into a real-time, programmable infrastructure based on multi-dimensional tensor modeling. By linking it to the clinical candidate discovery pipeline of a global multinational pharmaceutical company, a unique technological barrier has been established by incorporating cell-type-specific genetic gradient correction factors from the screening stage and eliminating batch effect deviations. Furthermore, by simultaneously constructing a genomic biomarker library that meets companion diagnostic (CDx) specifications, it will function as a central asset in digital healthcare, drastically shortening the FDA Investigational New Drug (IND) application review framework and the cGMP commercial launch approval timeline.
Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy with limited treatment options and high rates of resistance to first-line kinase inhibitors. Current therapies largely target the tumor microenvironment, leaving intrinsic tumor vulnerabilities underexplored. Here, we introduce a systems-based machine learning pipeline that integrates single-cell RNA sequencing, protein interaction networks, and drug proximity analysis to identify therapeutic targets in ccRCC. Candidate genes were refined using CRISPR screening data and functional relevance and validated across independent transcriptomic datasets. The pipeline recovered several established treatment pathways and uncovered previously underexplored therapeutic mechanisms, including ABL1, CDK4/6, and JAK inhibition. We identified FDA-approved compounds acting through these pathways, three of which, Ribociclib, Ponatinib, and Dasatinib, showed superior efficacy to current therapies across renal cancer cell lines in preclinical screens. By acting through mechanisms distinct from current therapies, they represent promising candidates for combination strategies aimed at overcoming resistance and improving clinical outcomes in ccRCC.
The systems ML-based multi-target discovery achievement of this study goes beyond theoretical exploration of renal cancer mechanisms and is directly applied to the actual global targeted anticancer drug market and the next-generation precision oncology business line.
First, by immediately scanning the ABL1/CDK4/6/JAK phosphorylation kinetics in the clinic using a multi-dimensional tensor Proximity ML pipeline, the temporal noise of tumor drug resistance recurrence is eliminated at the source, improving patient survival and maintaining reversible biological homeostasis.
At the same time, by linking to the open-source TCGA cohort database, which aggregates single-cell transcriptomic matrices, a companion diagnostic (CDx) panel interface is realized that can virtually simulate and correct for batch effect and immune heterogeneity confounding variables during clinical design and real-time reverse-calculate the effective docking concentration of Ribociclib, Ponatinib, and Dasatinib targets.
Furthermore, when a multinational company conducts a large-scale approval clinical trial for next-generation ccRCC drugs targeting intrinsic tumor vulnerabilities, by linking functional binding affinity data based on CRISPR knockout as a correction factor, batch-to-batch drug kinetic heterogeneity is eliminated, and it functions as a backbone infrastructure that maximizes the probability of obtaining regulatory approval and cGMP commercial launch approval from global regulatory agencies.